By synergizing vaccine and DNA technologies, Vical is creating new therapies, and shaping the future of vaccines. Our vision is to realize the promise of novel preventive and therapeutic alternatives for serious and life-threatening diseases.

Vical's core technology grew out of a chance discovery and provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy. 

Vical's management systematically leveraged that technology into a broad portfolio of independent and partnered product development programs. The first products for animal health are on the market. The first human products are approaching.